Literature DB >> 16252846

Prevalence of positive antinuclear antibodies in healthy children.

Siriwan Wananukul1, Wanlapa Voramethkul, Yadah Kaewopas, Orrawadee Hanvivatvong.   

Abstract

Antinuclear antibodies (ANA) frequently arise in the sera of children with connective tissue disease and is used in the diagnosis of these diseases. Therefore it is also important to know the prevalence of ANA in normal children. The main objective of the present study was to determine the prevalence of antinuclear antibody (ANA) in healthy children. Ninety-nine serum samples from a serum bank and 108 samples from patients who had attended elective surgery and whose blood had been withdrawn for other investigations, were tested for ANA by indirect immunofluorescence method using HEp-2 cells as substrate. Sera from 52 children with SLE were also tested during the same period. It was found that antinuclear antibodies were present in 32 (15%) of the 207 sera of healthy children at a dilution of 1:40 or higher. ANA were positive in 9% at a serum dilution of 1:40, in 3% at 1:80 and in 3% at 1:160. The patterns of immunofluorescence staining were as follows: homogeneous in 46.7%, speckled in 20%, and nucleolar in 10%. In SLE patients, ANA were positive in 91%; 13% at a serum dilution of 1:40, 7% at 1:80, 20% at 1:160, 15% at 1:320, 9% at 1:640, 20% at 1:1,280 and 9% at > or = 1:2,560. It was concluded that the prevalence of positive ANA using the HEp-2 cells as substrate was 15% in healthy children at dilutions of 1:40 or higher. Using the cutoff serum dilution of 1:40, the sensitivity of this test was 91%, the specificity was 85%, the positive predictive value was 57% and the negative predictive value was 97%.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16252846

Source DB:  PubMed          Journal:  Asian Pac J Allergy Immunol        ISSN: 0125-877X            Impact factor:   2.310


  15 in total

Review 1.  Do antiphospholipid antibodies develop for a purpose?

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 2.  Laboratory tests in pediatric rheumatology.

Authors:  Manjari Agarwal; Sujata Sawhney
Journal:  Indian J Pediatr       Date:  2010-08-26       Impact factor: 1.967

3.  Testing for Rheumatological Diagnoses in Children.

Authors:  Judith A Smith
Journal:  Eur Paediatr Rev       Date:  2009

Review 4.  Childhood cerebellar ataxia.

Authors:  Brent L Fogel
Journal:  J Child Neurol       Date:  2012-07-04       Impact factor: 1.987

5.  The influence of demography and referral medical specialty on the detection of autoantibodies to HEP-2 cells in a large sample of patients.

Authors:  Wilton Ferreira Silva Santos; Ana Paula de Castro Cantuária; Daniele de Castro Félix; Leandro Kegler Nardes; Igor Cabral Santos de Melo
Journal:  Adv Rheumatol       Date:  2022-08-15

6.  Autoantibodies in hepatitis C: red flag or bystander effect?

Authors:  Michele M Tana; Theo Heller
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-03       Impact factor: 2.839

7.  Significance of autoantibody seropositivity in children with obesity and non-alcoholic fatty liver disease.

Authors:  Toshifumi Yodoshi; Sarah Orkin; Ana Catalina Arce-Clachar; Kristin Bramlage; Stavra A Xanthakos; Marialena Mouzaki; Pamela L Valentino
Journal:  Pediatr Obes       Date:  2020-07-08       Impact factor: 3.910

Review 8.  Prevalence of autoantibodies in pediatric patients with idiopathic pulmonary hemosiderosis: a scoping review of the literature in the period 1980-2021.

Authors:  Biplab K Saha; Alyssa Bonnier; Praveen Chenna; Nils T Milman
Journal:  Clin Rheumatol       Date:  2022-01-24       Impact factor: 3.650

9.  Autoimmune hepatitis as a unique form of an autoimmune liver disease: immunological aspects and clinical overview.

Authors:  Hind I Fallatah; Hisham O Akbar
Journal:  Autoimmune Dis       Date:  2012-12-12

Review 10.  Biomarkers of mercury exposure in the Amazon.

Authors:  Nathália Santos Serrão de Castro; Marcelo de Oliveira Lima
Journal:  Biomed Res Int       Date:  2014-04-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.